Cargando…

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and MAPK altered colon and thyroid cancer models. In vitr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pairawan, Seyed, Akcakanat, Argun, Kopetz, Scott, Tapia, Coya, Zheng, Xiaofeng, Chen, Huiqin, Ha, Min Jin, Rizvi, Yasmeen, Holla, Vijaykumar, Wang, Jing, Evans, Kurt W., Zhao, Ming, Busaidy, Naifa, Fang, Bingliang, Roth, Jack A., Dumbrava, Ecaterina Ileana, Meric-Bernstam, Funda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786858/ https://www.ncbi.nlm.nih.gov/pubmed/35075200 http://dx.doi.org/10.1038/s41598-022-05193-z

Ejemplares similares

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
por: Pairawan, Seyed, et al.
Publicado: (2021)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
por: Owusu-Brackett, Nicci, et al.
Publicado: (2020)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
por: Meric-Bernstam, Funda, et al.
Publicado: (2012)

Epithelial to mesenchymal transition is associated with rapamycin resistance
por: Holder, Ashley M., et al.
Publicado: (2015)

Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy
por: Zeng, Jia, et al.
Publicado: (2014)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers
por: Kopetz, Scott, et al.
Publicado: (2019)

RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient
por: Bagheri-Yarmand, Rozita, et al.
Publicado: (2021)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
por: Saridogan, Turcin, et al.
Publicado: (2023)

Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo
por: Zhang, Xiaoshan, et al.
Publicado: (2022)

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
por: Saleh, Mansoor N., et al.
Publicado: (2021)

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
por: Huang, Licai, et al.
Publicado: (2022)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
por: Saleh, Mansoor N., et al.
Publicado: (2022)

The important role of MDM2, RPL5, and TP53 in mycophenolic acid-induced cleft lip and palate
por: Lin, Yangyang, et al.
Publicado: (2021)

Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling
por: Wang, Xiaoxuan, et al.
Publicado: (2021)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
por: Dumbrava, Ecaterina E. Ileana, et al.
Publicado: (2019)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
por: Busaidy, Naifa Lamki, et al.
Publicado: (2012)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2019)

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation
por: Chelariu-Raicu, Anca, et al.
Publicado: (2023)

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature
por: Korphaisarn, Krittiya, et al.
Publicado: (2017)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature
por: Chen, Guocai, et al.
Publicado: (2015)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women
por: Zając, Agnieszka, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0nt2smjdf359vo3ndgo536sosh